Please find information below on the invited Workshops that have been confirmed to-date for ANR2018. This information will be updated as the conference nears.
Wednesday May 9, 2018, 1:00-3:00 PM
– John Maris, MD (Children’s Hospital of Philadelphia)
– Nai-Kong Cheung, MD, PhD (Memorial Sloan Kettering Cancer Center, NY)
– Ira Mellman, PhD (Genentech Inc.)
– Crystal Mackall, MD (Stanford University, Stanford CA)
The immunotherapy workshop may include optimal preclinical models for immunotherapy, targeting the microenvironment, combination immunotherapies, cellular therapies with NK cells, CAR-T cells, vaccines, ongoing clinical trials, and toxicities.
Wednesday May 9, 2018, 3:30-5:30 PM
– Gudrun Schleiermacher, MD, PhD (Curie Institute, France)
– Michael Angelo, MD, PhD (Stanford University, Stanford CA)
– Allison Welsh, PhD (Foundation Medicine, Cambridge MA)
– Katleen de Preter, MD (Ghent University, Ghent, Belgium)
This workshop will provide a presentation and discussion of cutting-edge translational biomarker technologies for the study of Neuroblastoma. In the first half, an overview of new technologies for assessing tissue and circulating biomarkers will be presented, beginning with next-generation imaging technologies such as multiplexed ion beam imaging (MIBI) and cytometry by time of flight (CytOF). Technical approaches for liquid biopsies will also be discussed, highlighting different methodologies for the study of circulating tumor DNA (ctDNA), miRNA, CTCs, and other circulating molecules. In the second half, we will narrow our focus to ctDNA biomarkers, and discuss the challenges and opportunities for developing and validating ctDNA assays for clinical use. This will include a group discussion, focusing on opportunities for collaboration and pooling of data, as well as how we should be thinking about clinical utility and the possibility of integrating ctDNA into clinical practice
Thursday, May 10, 2018, 1:00-3:00 PM
– Jamie H. D. Cate, PhD (University of California, Berkeley)
– Nahum Sonenberg, PhD (McGill University, Montreal)
– Poul Sorensen, MD, PhD (University of British Columbia, Vancouver)
– Anne Willis, PhD (MRC Toxicology Unit, United Kingdom)
This workshop will explore the roles of altered mRNA translational regulation in cancer development, including how translation control influences adaptive responses to oncogenic stress, as well as pharmacological approaches to target the translation machinery in neuroblastoma.
Thursday May 10, 2018, 3:30-5:30 PM
– Donald Berry, PhD (The University of Texas MD Anderson Cancer Center)
– Gilles Vassal, PhD (Institut Gustave-Roussy, France)
– Brian Alexander, MD, MPH (Dana-Farber/Harvard Cancer Center)
– Yael Mosse, MD (Children’s Hospital of Philadelphia)
This workshop will examine and discuss challenges and best practices for effectively utilizing genetic information in the design and implementation of clinical trials to support the development of precision medicines, including exploring the potential advantages and disadvantages of such trials in neuroblastoma and across a variety of pediatric cancers.